Dr. Ronica Nanda is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Nanda will be located at Morton Plant Mease Hospital where she will support the partnership between Moffitt and BayCare. Dr. Nanda received her MD from the University of Florida. She completed a Radiation Oncology Residency at Emory University, where she also served as Chief Resident. She recently completed a Fellowship in Pediatric Proton Therapy at the University of Florida Health Proton Therapy Institute in Jacksonville. Dr. Nanda’s clinical interest is the treatment of breast cancers, lung cancers, brain tumors, and sarcomas. She also has a background in pediatric radiation oncology as well as in the use of proton therapy for adult and pediatric malignancies. Dr. Nanda’s primary research interests are on late effects of radiation therapy and cancer treatment. She has published numerous peer-reviewed manuscripts in high impact journals and has presented her research at multiple internationally-attended conferences. She is also passionate about studying survivorship issues for people with cancer. We are very excited to have Ronica join us and strengthen Moffitt’s ongoing relationship with the Baycare Health System.
Education & Training
University of Florida Health Proton Therapy Institute - Pediatric Proton Therapy
Emory University School of Medicine - Internal Medicine/Radiation Oncology
Mills M, Liveringhouse C, Lee F, Nanda RH, Ahmed KA, Washington IR, Thapa R, Fridley BL, Blumencranz P, Extermann M, Loftus L, Balducci L, Diaz R. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2- breast cancer and is associated with inferior outcomes. Geriatr Oncol. 2021 Mar.12(2):219-226. Pubmedid: 32859560. Pmcid: PMC7907245.
Dohm A, Diaz R, Nanda RH. The Role of Radiation Therapy in the Older Patient. Curr Oncol Rep. 2021 Jan.23(1):11. Pubmedid: 33387104.
Jim HSL, Hoogland AI, Brownstein NC, Barata A, Dicker AP, Knoop H, Gonzalez BD, Perkins R, Rollison D, Gilbert SM, Nanda R, Berglund A, Mitchell R, Johnstone PAS. Innovations in research and clinical care using patient-generated health data. CA-Cancer J Clin. 2020 May.70(3):182-199. Pubmedid: 32311776. Pmcid: PMC7488179.
Brown P, Inaba H, Annesley C, Beck J, Colace S, Dallas M, DeSantes K, Kelly K, Kitko C, Lacayo N, Larrier N, Maese L, Mahadeo K, Nanda R, Nardi V, Rodriguez V, Rossoff J, Schuettpelz L, Silverman L, Sun J, Sun W, Teachey D, Wong V, Yanik G, Johnson-Chilla A, Ogba N. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2020 Jan.18(1):81-112. Pubmedid: 31910389.
Mills MN, Russo NW, Nanda RH, Wilson JP, Altoos TA, Caldwell DL, Stout LL, Dube S, Blumencranz PW, Allen KG, Diaz R. Management of ductal carcinoma in situ with accelerated partial breast irradiation brachytherapy: Implications for guideline expansion. Brachytherapy. 2020 Dec.20(2):345-352. Pubmedid: 33317964.
Indelicato DJ, Bradley JA, Rotondo RL, Nanda RH, Logie N, Sandler ES, Aldana PR, Ranalli NJ, Beier AD, Morris CG, Mendenhall NP. Outcomes following proton therapy for pediatric ependymoma. Acta Oncol. 2018 May.57(5):644-648. Pubmedid: 29239262.
Mokhtech M, Rotondo RL, Bradley JA, Sandler ES, Nanda R, Logie N, Aldana PR, Morris CG, Indelicato DJ. Early outcomes and patterns of failure following proton therapy for nonmetastatic intracranial nongerminomatous germ cell tumors. Pediatr Blood Cancer. 2018 Jun.65(6):e26997. Pubmedid: 29380526.
Morgan TM, Danish H, Nanda RH, Esiashvili N, Meacham LR. Whole lung irradiation in stage IV Wilms tumor patients: Thyroid dosimetry and outcomes. Pediatr Blood Cancer. 2018 Feb.65(2). Pubmedid: 28960781.
Cassidy RJ, Zhang X, Switchenko JM, Patel PR, Shelton JW, Tian S, Nanda RH, Steuer CE, Pillai RN, Owonikoko TK, Ramalingam SS, Fernandez FG, Force SD, Gillespie TW, Curran WJ, Higgins KA. Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer. 2018 Feb.124(4):775-784. Pubmedid: 29315497. Pmcid: PMC5801133.
Nanda R, Flampouri S, Mendenhall NP, Indelicato DJ, Jones LM, Seeram VK, Hoppe BS. Pulmonary Toxicity Following Proton Therapy for Thoracic Lymphoma. Int J Radiat Oncol Biol Phys. 2017 Oct.99(2):494-497. Pubmedid: 28872001.
Nanda RH, Ganju RG, Schreibmann E, Chen Z, Zhang C, Jegadeesh N, Cassidy R, Deng C, Eaton BR, Esiashvili N. Correlation of Acute and Late Brainstem Toxicities With Dose-Volume Data for Pediatric Patients With Posterior Fossa Malignancies. Int J Radiat Oncol Biol Phys. 2017 Jun.98(2):360-366. Pubmedid: 28463155.
Nanda RH, Shehata BM, Khoshnam N, Durham M, Kim S, Selwanes W, Chen Z, Zhang C, Esiashvili N. Impact of lymph node evaluation in adjuvant and neoadjuvant chemotherapy settings on survival outcomes in Wilms tumour: a review of 185 cases from a single institution. Pathology. 2017 Jan.49(1):19-23. Pubmedid: 27913041.
Sayan M, Cassidy RJ, Butker EE, Nanda RH, Krishnamurti L, Khan MK, Esiashvili N. Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. Bone Marrow Transplant. 2016 Jul.51(7):997-998. Pubmedid: 26950374.
Abugideiri M, Nanda RH, Butker C, Zhang C, Kim S, Chiang KY, Butker E, Khan MK, Haight AE, Chen Z, Esiashvili N. Factors Influencing Pulmonary Toxicity in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of Total Body Irradiation-Based Myeloablative Conditioning. Int J Radiat Oncol Biol Phys. 2016 Feb.94(2):349-359. Pubmedid: 26853343.
Ganju RG, Nanda RH, Esiashvili N, Switchenko JM, Wasilewski-Masker K, Marchak JG. The Effect of Transition Clinics on Knowledge of Diagnosis and Perception of Risk in Young Adult Survivors of Childhood Cancer. J Pediat Hematol Onc. 2016 Apr.38(3):197-201. Pubmedid: 26925717. Pmcid: PMC4937789.
Kirkland RS, Nanda RH, Alazraki A, Esiashvili N. Influence of Pulmonary Nodules on Chest Computed Tomography and Risk of Recurrence in Stage IV Wilms Tumor. Int J Radiat Oncol Biol Phys. 2015 Jun.92(2):332-338. Pubmedid: 25754630.
Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015 Jun.111(8):1028-1034. Pubmedid: 26073887.
Nanda RH, Liu Y, Gillespie TW, Mikell JL, Ramalingam SS, Fernandez FG, Curran WJ, Lipscomb J, Higgins KA. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis. Cancer. 2015 Dec.121(23):4222-4230. Pubmedid: 26348268.
Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N. Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma. J Pediat Hematol Onc. 2015 Apr.37(3):175-180. Pubmedid: 25238225. Pmcid: PMC4869887.
Nanda R, Dhabbaan A, Janss A, Shu HK, Esiashvili N. The feasibility of frameless stereotactic radiosurgery in the management of pediatric central nervous system tumors. J Neurooncol. 2014 Apr.117(2):329-335. Pubmedid: 24549752.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub